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Background: Artemisinin-based combination therapy (ACT) for treating malaria has activity against immature
gametocytes. In theory, this property may complement the effect of terminating otherwise lengthy malaria
infections and reducing the parasite reservoir in the human population that can infect vector mosquitoes. However,
this has never been verified at a population level in a setting with intense transmission, where chronically infectious
asymptomatic carriers are common and cured patients are rapidly and repeatedly re-infected.
Methods: From 2001 to 2004, malaria vector densities were monitored using light traps in three Tanzanian districts.
Mosquitoes were dissected to determine parous and oocyst rates. Plasmodium falciparum sporozoite rates were
determined by ELISA. Sulphadoxine-pyrimethamine (SP) monotherapy was used for treatment of uncomplicated
malaria in the contiguous districts of Kilombero and Ulanga throughout this period. In Rufiji district, the standard
drug was changed to artesunate co-administered with SP (AS + SP) in March 2003. The effects of this change in case
management on malaria parasite infection in the vectors were analysed.
Results: Plasmodium falciparum entomological inoculation rates exceeded 300 infective bites per person per year at
both sites over the whole period. The introduction of AS + SP in Rufiji was associated with increased oocyst
prevalence (OR [95%CI] = 3.9 [2.9-5.3], p< 0.001), but had no consistent effect on sporozoite prevalence (OR [95%
CI] = 0.9 [0.7-1.2], p = 0.5). The estimated infectiousness of the human population in Rufiji was very low prior to the
change in drug policy. Emergence rates and parous rates of the vectors varied substantially throughout the study
period, which affected estimates of infectiousness. The latter consequently cannot be explained by the change in
drug policy.
Conclusions: In high perennial transmission settings, only a small proportion of infections in humans are
symptomatic or treated, so case management with ACT may have little impact on overall infectiousness of the
human population. Variations in infection levels in vectors largely depend on the age distribution of the mosquito
population. Benefits of ACT in suppressing transmission are more likely to be evident where transmission is already
low or effective vector control is widely implemented.
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Currently, artemisinin-based combination therapy (ACT)
is used as first-line treatment of uncomplicated malaria in
most countries in sub-Saharan Africa. In addition to killing
the asexual blood stages that cause disease and, therefore,
terminating otherwise lengthy, persistently transmissible
infections [1-3], artemisinins are gametocytocidal, killing
the immature sexual stages of malaria parasites eventually
responsible for infecting mosquitoes [4,5]. While non-
gametocyctocidal drugs will also cure otherwise lengthy
infections and reduce the period of infectiousness to mos-
quitoes, gametocytes will remain in the cured individual
for some time, allowing for transmission.
In principle, through their combined impacts upon
both the short-term infectiousness of treated individuals,
and perhaps more importantly [6], upon the long-term
duration of infection and therefore infectiousness, ACT
might reduce the reservoir of parasites in the human
population that eventually infects mosquitoes.
The provision of ACT for treatment of uncomplicated
malaria has been associated with reduced malaria inci-
dence in diverse settings with modest transmission in-
tensity [4,7,8]. This implies that ACT may effectively
reduce human-to-mosquito and consequently mosquito-
to-human transmission under normal conditions of pro-
grammatic use, as has been suggested in individually ran-
domized, controlled trials evaluating the infectiousness
of patients receiving ACT [9-11].
Determination of the proportion of humans harbouring
gametocytes following ACT treatment may not accurately
estimate human population infectiousness since infec-
tiousness seems only loosely correlated to gametocyte
density [12,13]. In malaria-endemic settings, humans can
be infectious to mosquitoes even in the absence of patent
gametocytaemia, regardless of treatment [1,14-16]. While
human-to-mosquito feeding experiments with laboratory-
reared mosquitoes are very useful, they do not capture
parasite infection and selection dynamics in the context
of their human host populations [17-20] and are not ne-
cessarily representative of the wild mosquito populations
which have natural feeding biases influenced by host age
and infection status [21-24]. Estimation of the human in-
fectious reservoir therefore requires analysis of the infec-
tion status of wild-caught mosquitoes.
A pre-post observational study with a contemporaneous
comparison group was used to evaluate the impact of case
management with ACT delivered through fixed health facil-
ities in two sites in rural Tanzania with intense malaria
transmission [25]. Both the intervention and comparison
sites used sulphadoxine-pyrimethamine (SP) as first-line
treatment of malaria in 2001–2003. In March 2003, the
ACT, artesunate co-administered with SP (AS+SP), was
introduced as a first-line treatment of malaria in the inter-
vention site while SP continued to be used for first-linetreatment in the comparison site. To assess the impact of
ACT introduction on malaria transmission, concurrent
measures of oocyst and sporozoite prevalence in the mos-
quito-vector population in both the intervention and com-
parison districts, before and after the introduction of
AS+SP, were carried out and used to directly determine
the infectiousness of the human population to mosquitoes,
and of mosquitoes to humans.
Methods
Study site
This study was conducted in two rural sites in southeast-
ern Tanzania. Rufiji District, the intervention site, is
located at the mouth of the Rufiji River, extends across
latitudes 7° 47′ and 8° 03′S and longitudes 38° 62′ and 39°
17′E with a population of about 202,001 inhabitants
[26,27]. Kilombero and Ulanga Districts, the comparison
site, form the valley of the Kilombero River, one of the
main tributaries of the Rufiji and are situated between lati-
tudes 8°00'–8°35'S, longitudes 35°58'–36°48'E and have
a combined population of 514,891 inhabitants [27,28]
(Figure 1). Both Rufiji and Kilombero-Ulanga Districts
have achieved relatively high coverage of largely untreated
bed nets [29,30] and are characterized by a hot climate
with an erratic rainy season from November to May. In
Rufiji, the average annual precipitation is 800–1,000 mm
while Kilombero-Ulanga receives 1,200-1,800 mm. In both
settings, malaria caused largely by Plasmodium falciparum
[31] is one of the biggest health problems perceived by the
local community and reported by the health services [32].
It is primarily transmitted by Anopheles gambiae, Anoph-
eles arabiensis and Anopheles funestus. Transmission is in-
tense and perennial despite marked seasonality in
mosquito densities, which peak with the rains [31,33].
Study design
The detailed description of the study is reported else-
where [25]. Briefly, a pre-post observational study with a
non-randomized comparison site was conducted. Both
sites used SP monotherapy as a first-line anti-malarial
delivered through health facilities from 2001. In March
2003, the Council Health Management Team implemen-
ted AS+ SP combination therapy as the first-line anti-
malarial provided free of charge through all the fixed
health facilities in Rufiji District, the intervention site. SP
monotherapy continued to be the first-line anti-malarial
in Kilombero-Ulanga, the comparison site, as well as in
the rest of the country. Here, SP was available free of
charge only to pregnant women and children under five
years of age.
Mosquito data collection
In each site, anopheline indoor biting rates were determined
by overnight trapping of host-seeking mosquitoes using
Figure 1 Map of the study districts. A: Rufiji; B: Kilombero; C: Ulanga.
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traps. The two sites used slightly different household selec-
tion procedures. Sampling in Kilombero-Ulanga occurred
from October 2001 to August 2004 and was based on
repeated sampling every six months of 25 clusters of house-
holds selected by stratified random sampling, using the
sub-village (kitongoji) as the first level and index household
as the second level of randomization [29]. Trapping was
carried out on 538 different nights, with an average of 4.9
traps per night. The traps were clustered in houses around
the index house, but out of sight of each other.
In Rufiji, the period sampled included a 17-month pre-
intervention period of October 2001 to February 2003 and
a 19-month post-intervention period of March 2003 to Sep-
tember 2004. Individual households were randomly selected
monthly from the same demographic surveillance sample
frame used for surveys of human malaria infection [25].
Trapping was carried out on 850 distinct dates, with an
average of 6.6 traps per night.
Light traps were installed about 0.5 m above the floor,
next to the foot of the bed of the selected person who slept
under a mosquito net. No attempt was made to differentiate
between treated and untreated nets in the field as thisproved impractical during routine field surveys and insecti-
cide treatment has only a minor effect on sampling effi-
ciency [29,34]. On occasions when the selected individual
for light trap sampling lacked a net, he or she was provided
with an untreated net for the nights during which they
participated.
Once collected, mosquitoes were counted and sorted
by species in the field. Where this was feasible, blood-fed
female An. gambiae s.l. and An. funestus were held in a
cup and fed on sugar water until the blood meal was
digested, this period ranges from two to three days de-
pending on temperature. Then, the mid-guts of these
mosquitoes were dissected in normal saline and stained
with 2% mercurochrome for examination of oocysts by
light microscopy [35]. The remaining parts of the dis-
sected mosquitoes as well as other undissected anophe-
lines were routinely stored in Eppendorf tubes with
a small quantity of silica gel. Mosquitoes were subse-
quently independently tested for circumsporozoite pro-
tein (CSP) by ELISA [36] in a central laboratory
at Ifakara Health Institute. At each site, a different tech-
nician conducted the mosquito dissections and examina-
tions for the presence of oocysts. Laboratory technicians
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status and source of the mosquitoes to avoid possible
biases in the determination of sporozoite infection
status.
Ethical approval
Ethical approval was obtained from the Medical Re-
search Coordination Committee of the National Medical
Research Coordination Committee of National Institute
for Medical Research, Tanzania (Reference number
NIMR/HQ/R.8a/VOL.VIII, dated April 2000).
Data analysis
The overall objective of the analysis was to determine
the relationship between the introduction of ACT and
the infectiousness of the human population, as reflected
by infection prevalence in local vector populations. The
outcome measures reflecting human-to-mosquito trans-
mission were the infection status of individual mosqui-
toes, with the primary and secondary effects defined by
the presence of oocysts or sporozoites, respectively,
within the two study zones. The proportions of mosqui-
toes with oocysts and sporozoites (the oocyst and sporo-
zoite rates, respectively) were estimated independently
for groups of mosquitoes collected before and after the
introduction of ACT in the intervention site. Multivari-
ate logistic regression models with terms for study site
(intervention versus comparison), period of mosquito
collection (pre-intervention versus post-intervention),
intervention (availability of ACT versus SP monother-
apy), and species of mosquito (An. gambiae s.l. versus
An. funestus), were used to assess the impact of the
introduction of ACT on oocyst and sporozoite preva-
lence. Statistical significance was defined as a p-value
≤0.05. All statistical analyses were executed using SPSS
15.0 (SPSS Inc, Chicago, USA).
To measure mosquito-to-human malaria transmission
intensity, the entomological inoculation rate (EIR) was
calculated by multiplying the arithmetic mean mosquito-
biting rate per night by the mean sporozoite prevalence
for that vector species. EIR was calculated separately for
the pre- and post- intervention periods. The biting rate
for each mosquito species was obtained by dividing the
mean catch of females in CDC light traps by published
estimates from the Kilombero Valley of the relative sensi-
tivity of CDC light traps relative to human landing
catches of 0.30 and 0.68 for An. gambiae s.l. and An.
funestus, respectively [37].
Infectiousness of humans to mosquitoes depends on K,
the proportion of mosquitoes that are infected at any given
feed. This cannot be measured directly, because infected
mosquitoes may have received their infections either at the
latest, or at a previous feed. There are various algorithms
for estimating K from field-caught mosquitoes. All of theserequire both a measure of the proportions of mosquitoes
that are infected, and a measure of the age distribution of
the vectors. For the present study, K was estimated from
the proportions of host-seeking mosquitoes with oocysts
and the proportion that were parous using the following
equation [38,39]:
KO ¼
1− 1M
1−MR
Where: M is the proportion of parous mosquitoes
among those dissected and R is the proportion of dis-
sected mosquitoes with oocysts (the immediate oocyst
rate). The standard error of KO was determined as
described previously [38].
Results
In Rufiji, 11,883 An. gambiae s.l. and 13,434 An. funestus
were sampled before ACT introduction, while 5,826 An.
gambiae s.l. and 2,626 An. funestus were sampled after
ACT introduction. In the comparison site: Kilombero-
Ulanga, 50,694 An. gambiae s.l. and 9,615 An. funestus
were sampled before and 27,559 An. gambiae s.l. and
8,381 An. funestus after ACT introduction in Rufiji. The
density of anophelines as well as the parous rate varied
seasonally and strongly between years (Figures 2 and 3).
Fewer mosquitoes were caught post the intervention
in Rufiji, but both 2003 and 2004 were very dry years
(Figure 4) and this was presumably the main factor
affecting mosquito densities.
Oocyst prevalence in Rufiji increased substantially be-
tween the pre-intervention and post-intervention period
(χ2 = 11.9, p <0.001 for An. gambiae, χ2 = 11.1, p <0.001
for An. funestus) with an odds ratio (estimated from a
multivariable logistic regression, allowing for site, spe-
cies, and time period) of 3.9 [95%CI: 2.9-5.3] (Figure 5).
However, the confidence intervals for both An. funestus
and An. gambiae s.l. oocyst rates were wide (Figures 2
and 3 respectively) because of the considerable inter-
month variation. No significant changes (χ2 = 0.01, p =0.9
for An. gambiae, χ2 = 0.04, p = 0.8 for An. funestus) were
observed in Kilombero-Ulanga (Table 1, Figures 2,3 and
4). Sporozoite prevalence also increased significantly in
Rufiji for An. funestus (χ2 = 37.3, p< 0.001), but not for
An. gambiae s.l. (χ2 = 0.02, p =0.9) so overall there was
little effect (OR [95%CI] = 0.9[0.7-1.2], p = 0.51) (Table 2)
while in Kilombero-Ulanga the sporozoite prevalence
increased significantly for An. gambiae s.l. (χ2 = 21.6,
p<0.001), but not for An. funestus (χ2 = 1.7, p =0.19).
These formal statistical comparisons between pre- and
post-intervention periods must be viewed cautiously in
the context of the considerable seasonal and inter-annual
variation in both mosquito densities, and in the numbers
of mosquitoes that were analysed for each outcome. The
Figure 2 Anopheles gambiae s.l. density (panels a and e), proportion parous (panels b and f), proportion with oocysts (panels c and f)
and proportion with sporozoites (panels d and g) for Kilombero-Ulanga (panels a – d) and Rufiji (panels e – g) districts by month.
Horizontal black lines represent observed values, grey bars represent 95% confidence intervals. Subsequent non-missing values are connected by
thin black lines.
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cated by the parous rates, also varied considerably over
time, reflecting variations in both mosquito survival and
recruitment rate to the vector populations. Environmen-
tal variation (Figure 4) is probably the main determinant
of longitudinal patterns in mosquito bionomics. Because
of the profound inter-annual differences we did not at-
tempt to adjust these analyses for seasonality.
Mosquito-to-human transmission, as estimated by the
EIR, consistently exceeded 300 infective bites per person
per year in both sites throughout the study period
(Table 1). During both the pre-intervention and post-
intervention time periods, the intervention site had thehighest proportion of sporozoite-positive mosquitoes
and, therefore, the highest EIR. The estimated EIR for
both An. gambiae s.l. and An. funestus in the interven-
tion site was higher after ACT introduction than before.
This coincided with a possible increase in human-to-mos-
quito transmission implied by the observed increase in oo-
cyst prevalence. In the absence of an increase in prevalence
of sporozoites in An. gambiae s.l. it is impossible to draw
any firm conclusions about effects on the infectious reser-
voir, which does not necessarily follow the EIR in endemic
settings [39]. One clear conclusion though is that the intro-
duction of ACT was not followed by signs of a decline in
human-mosquito transmission.
Figure 3 Anopheles funestus density (panels a and e), proportion parous (panels b and f), proportion with oocysts (panels c and f) and
proportion with sporozoites (panels d and g) for Kilombero-Ulanga (panels a – d) and Rufiji (panels e – g) districts by month. Horizontal
black lines represent observed values, grey bars represent 95% confidence intervals. Subsequent non-missing values are connected by thin black
lines.
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population were summarized at the level of the time
period (pre- or post-policy change), by site, and by
vector species (Table 3). The values of KO were simi-
lar for both vector species, both sites and both time
periods, with the exception of the pre-intervention
values for Rufiji, which were very low. Much of the
variation in sporozoite and oocyst prevalence can
thus be attributed to variations in mosquito survival,
which are accounted for by the term for the parous
rate (M) in the formula for KO.
The values estimated for K in the literature are ex-
tremely variable [39] but few of them are as low as thevalues measured pre-intervention in Rufiji. The values
for Kilombero-Ulanga do not show any indication of a
trend over time, and are higher than the pre-intervention
Rufiji ones, suggesting that the low values cannot be
attributed to the use of SP as treatment. There is no in-
dication that the post-policy change values for Rufiji
reduced K below the Kilombero value.
Discussion
Despite numerous clinical studies demonstrating high cure
rates and gametocytocidal effect of artemisinin derivatives
[9,10,40,41], there is no evidence that this translates into
any measurable impact on malaria transmission intensity
020
40
60
80
100
120
140
160
180
2002 2003 2004
M
ea
n 
ra
in
fa
ll 
(m
m)
0
5
10
15
20
25
30
35
40
M
ea
n 
te
m
pe
ra
tu
re
 (C
)
Figure 4 Temperature and rainfall for Rufiji for the period of
2002–2004. The bars represent the rainfall per month (left axis), the
lines show the monthly maximum (solid line) and minimum
temperature (broken line), right axis. Values are based on remote
sensing. Rainfall data were obtained from the Africa Data
Dissemination Service (ADDS) [53] and temperature data from the
National Aeronautics and Space Administration [54].
a
c
e
0.00 
0.03 
0.06 
0.09 
0.12 
0.15 
Sp
or
oz
oi
te
 p
re
va
le
nc
e 
0 
100
200
300
400
500
600
EI
R
 p
er
 Y
ea
r 
0.00 
0.01 
0.02 
0.03 
0.04 
0.05 
0.06 
Before After
Before After
Before After
O
oc
ys
t p
re
va
le
nc
e 
Sp only
agnalU-orebmoliK
Figure 5 Trends in mosquito infection prevalence. Observed trends of
after the onset of an artesunate-based effectiveness trial, error bars correspo
Anopheles gambiae s.l. (straight line and dark squares) and Anopheles funest
transmission. The shading on the graphs serves to indicate the transition fr
Huho et. al. Malaria Journal 2012, 11:118 Page 7 of 12
http://www.malariajournal.com/content/11/1/118at the population level in these Tanzanian sites. Although,
the potential to reduce malaria transmission is widely
cited, some mathematical models predict only a modest
incremental impact of the routine use of ACT over non-
gametocytocidal drugs in high transmission settings [19].
This observational study of the impact of routine delivery
of ACT via health facilities provides some empirical sup-
port for this. Although, the parasitological study found a
significant reduction in asexual parasitaemia prevalence
following ACT introduction, this reduction was very mod-
est (five percentage-points) and was not reflected in a
measurable reduction of gametocytaemia prevalence in the
human population [25] . In the present study, the most
direct indicator of human-to-mosquito transmission,
namely oocyst prevalence, was substantially higher after
ACT introduction. It is unclear what caused this increase,
particularly since the sporozoite prevalence did not in-
crease at the same time (Table 2), only factors, in particular
weather patterns (Figure 4) changed considerably betweenb
f
d
Before After
Before After
Before After
As+Sp
Rufiji 
mosquito oocyst (a & b) and sporozoite (c & d) prevalence before and
nd to 95% confidence interval. A comparison can be made for
us (dotted line, white squares). Panels E & F show the trends in malaria
om before and after the addition of AS to SP.
Table 1 Prevalence of mosquitoes infected with oocysts and sporozoites and entomological inoculation rate (EIR) in
Rufiji and Kilombero-Ulanga Districts by Anopheline species and time period
Time period (Anti-malarial in use) Oocyst prevalence Sporozoite prevalence EIR
n/N % [95% CI] n/N % [95% CI]
Rufiji
An. funestus January 2002-February 2003 (SP) 9/1094 0.82 [0.29-1.36] 321/14861 0.022 [0.019-0.024] 108
March 2003- September 2004 (AS + SP) 11/330 3.33 [1.40-5.27] 99/2273 0.044 [0.035-0.052] 288
An. gambiae s.l January 2002-February 2003 (SP) 4/475 0.84 [0.02-1.66] 291/8665 0.034 [0.030-0.037] 332
March 2003-September 2004 (AS + SP) 51/1195 4.27 [3.12-5.41] 215/6475 0.033 [0.029-0.038] 538
Kilombero-Ulanga
An. funestus January 2002-February 2003 (SP) 31/2518 1.23 [0.80-1.66] 63/4353 0.014 [0.011-0.018] 45
March 2003- August 2004 (SP) 21/1806 1.16 [0.67-1.66] 117/6576 0.018 [0.015-0.021] 50
An. gambiae s.l January 2002-February 2003 (SP) 40/4506 0.89 [0.61-1.16] 63/9333 0.007 [0.005-0.008] 267
March 2003- August 2004 (SP) 24/2765 0.87 [0.52-1.21] 128/9372 0.014 [0.011-0.016] 320
EIR = Entomological inoculation rate expressed as infectious mosquito bites per person per year.
95% CI = 95% confidence interval.
SP = Sulphadoxine-pyrimethamine.
AS + SP=Artesunate co-administered with sulphadoxine-pyrimethamine.
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availability of mosquitoes for analysis varied erratically
throughout the study period, it is not possible to formally
separate inter-annual and seasonal variation from effects
of the policy change, but the overall conclusion is that any
ACT-related reductions in human-to-mosquito or mos-
quito-to-human transmission in the mosquito population
were small.
Overall, these two large-scale, complementary studies of
malaria parasite prevalence in both humans andTable 2 Factors associated oocyst and sporozoite prevalence
Districts, January 2002-July 2004
Variable Oocyst prevalen
OR [95% CI]
District
Kilombero-Ulanga Referent
Rufiji 0.72 [0.38-1.37]
Period
January 2002-February 2003 Referent
March 2003-July 2004 1.09 [0.76-1.58]
Anti-malarial in use
SP Referent
AS + SP 3.91 [2.88-5.33]
Anopheline species
An. gambiae s.l Referent
An. funestus 1.19 [0.88-1.61]
95% CI = 95% confidence interval.
SP = Sulphadoxine-pyrimethamine.
AS + SP=Artesunate co-administered with sulphadoxine-pyrimethamine.mosquitoes did not detect any epidemiologically meaning-
ful suppression of human population infectiousness fol-
lowing ACT introduction. However, mosquito population
dynamics in Rufiji were clearly profoundly affected by var-
iations in rainfall during the study period. Rainfall affects
both the emergence rates of vectors, and probably (via
effects on humidity) the survival of adult mosquitoes. This
does not directly affect the infectiousness of the human
population to mosquitoes, but has profound effects on
malaria transmission as measured either by the EIR or thein Anopheline vectors in Rufiji and Kilombero-Ulanga
ce Sporozoite prevalence
P value OR [95% CI] P value
Referent Referent Referent
0.31 2.51 [2.22-2.84] <0.001
Referent Referent Referent
0.63 1.44 [1.28-1.61] <0.001
Referent Referent Referent
<0.001 0.92 [0.72-1.18] 0.51
Referent Referent Referent
0.26 0.96 [0.85-1.07] 0.45
Table 3 Oocyst-based estimates of human
infectiousness (Ko)
Time Period
(Anti-malaria
in use)
Ko [95%CI]
Rufiji
An funestus January 2002-February 2003
(SP)
0.011 [0.000 - 0.016]
March 2003-September 2004
(AS + SP)
0.029 [0.013 - 0.054]
An gambiae s.l. January 2002-February 2003
(SP)
0.006 [−0.009 - 0.013]
March 2003-September 2004
(AS + SP)
0.042 [0.028 - 0.057]
Kilombero-Ulanga
An funestus January 2002-February 2003
(SP)
0.034 [−0.001 - 0.025]
March 2003-August 2004
(SP)
0.019 [−0.001 - 0.021]
An gambiae s.l. January 2002-February 2003
(SP)
0.032 [0.000 - 0.020]
March 2003-August 2004
(SP)
0.024 [−0.005 - 0.025]
Huho et. al. Malaria Journal 2012, 11:118 Page 9 of 12
http://www.malariajournal.com/content/11/1/118oocyst prevalence. The large variations in emergence rates
and survival of mosquitoes very likely account for most of
the variation in oocyst prevalence, though this cannot ex-
plain why infectiousness was so low during the first half of
the study (prior to ACT) in Rufiji, or why the oocyst preva-
lence increased after ACT introduction, while sporozoite
prevalence did not. Far fewer mosquitoes were examined
for oocysts than sporozoites, and sampling variation thus
contributes more to the oocyst data.
The increase in oocyst prevalence thus seems very un-
likely to be related to the change in drug policy. Nor is it
likely that any substantive change in coverage of bed nets
could have contributed to the observed difference in oo-
cyst rates because net ownership and use remained rela-
tively low and stable in Rufiji District until late 2005.
There were no major changes in availability of nets in
Kilombero-Ulanga during the study period [30].
Although an efficacious ACT with known gametocytoci-
dal properties was deployed and achieved reasonable
population level coverage with an estimated 0.6 to 2.2
AS+SP treatments per person per year, the majority of
persons receiving treatment with ACT were symptomatic
children. Thus, the asymptomatic, chronically infected,
semi-immune older children and adults who likely consti-
tuted the bulk of the reservoir of gametocytes [23] were
relatively untouched by the introduction of ACT for case
management. There have even been suggestions of higher
infectivity of gametocytes in asymptomatic carriers in
comparison to symptomatic cases due to the large quantityof gametocytes in the former group [42]. In areas where
the initial level of malaria transmission is relatively low,
the ratio of symptomatic to asymptomatic infections is
higher, and larger proportionate reductions in transmis-
sion may be likely following introduction of ACT
[6,39,43]. Conversely, in areas of high transmission such as
investigated here, ACT may have little impact on preva-
lence, human population infectiousness and consequent
mosquito-to-human transmission because a greater pro-
portion of infections are only mildly symptomatic. Fur-
thermore, even in settings such as these where
artemisinins are combined with complementary partner
drugs, such as SP which have long-lasting prophylactic
effects [19], ACT use may have little impact on overall
transmission where it occurs at high intensities simply be-
cause individuals often become re-infected within weeks
of treatment [1].
ACT might only have a substantial effect on the infec-
tious reservoir if most of the infections are actually being
treated with this drug class. The delivery of ACT through
public sector outlets in Rufiji rose steadily from 2003 to
2005 with a total of 450,000 doses being deployed for dis-
tribution to all registered health facilities by that time [44],
corresponding to a mean consumption rate of 2.22 doses
per person per year. Adherence among recipients has been
estimated at 75% [45], which implies that this drug was
delivered reasonably effectively. The proportion of care-
seeking visits made to the health facilities that were fever-
related rose from 31.8% in 2001 to 54.7% in 2004 [46], per-
haps due to improved community perceptions, availability
and affordability. Recent calls for accurately targeting ACT
only to those with patent parasitaemia [47] may, paradox-
ically, further undercut the potential for case management
alone to contribute to transmission reduction in highly en-
demic settings.
While much emphasis has been placed upon the im-
portance of the gametocytocidal properties of ACT, their
most important contribution to lowering human popula-
tion infectiousness is to terminate otherwise long-lasting
infections with asexual stages, which intermittently but
persistently generate gametocytes and can infect mosqui-
toes for over a year [19]. This is comparable to the effect
of non-gametocytocidal blood schizonticides. Similarly,
the impact of curative drugs upon onward transmission
is probably primarily determined by the length of time
successfully treated patients remain uninfected and con-
sequently non-infectious, rather than whether that drug
kills the relatively short-lived gametocytes already
present at the time of administration. Therefore, while
an effective cure may reduce human population infec-
tiousness in an area with little transmission, in parts of
Africa where it is common to become re-infected within
weeks or even days, even regular treatment of symptomatic
infections [48,49] will likely have only a modest effect upon
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Conclusions
Whilst it is disappointing that no obvious reduction of
human infectiousness was evident after introduction of
ACT for malaria case management in this first large-area
trial in a region of intense transmission, perhaps this is
not entirely surprising. Both rapid re-infection and semi-
immune, chronically infectious, asymptomatic carriers
are common in such settings. The lack of any such sec-
ondary benefits in high transmission areas should not
detract from the direct public health value of ACT as a
means to treat uncomplicated malaria and prevent severe
disease manifestations. As has already been outlined in
both theory [19] and practice [8,11], effective chemother-
apy with ACT has a vital role in reducing malaria mor-
bidity and mortality. The contribution of chemotherapy
to the control and elimination of transmission is likely to
be most valuable in settings where transmission is either
naturally low or where other approaches such as effective
vector control have brought it down to more tractable
levels.
There is a need for entomological surveys in parallel to
clinical surveillance as a routine component of large-
scale trials of anti-malarial drugs or vaccines, but varia-
tions in space and time in entomological data should not
ignored. Malaria parasite prevalence in vector popula-
tions may serve as a useful indicator of the population-
wide effect of deployment of interventions that may have
only previously been evaluated in individual participants
in clinical trials. There is also a need for more cost-ef-
fective technologies and procedures for sampling vector
mosquito populations across large areas [50,51] to enable
accurate and precise measurement of their infection
prevalence.
Finally, although there was no demonstrable impact
of introducing ACT free for routine case manage-
ment without diagnostic confirmation, this should
not discourage malaria control programmes and their
development partners from rolling out interventions
to enhance ACT coverage and improve targeting
through existing diagnostic tests. Since the study was
conceived, ACT and effective vector control through
insecticide-treated bed nets have been scaled up
broadly, coinciding with substantial reductions in
malaria-related and all-cause child mortality in areas
of highly endemic malaria transmission [52]. These
findings suggest that untargeted ACT alone may have
limited impact on transmission. Endemic countries
and their development partners should continue to
promote ACT and confirmed diagnosis, but may wish
to reconsider their expectations of what effect this
may have on malaria transmission. Scaling-up andsustaining effective case management along with
proven vector control interventions remains the pri-
ority for these areas.
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